Keytruda Qlex (Subcutaneous Pembrolizumab + Berahyaluronidase) Receives FDA Approval
In this article
Speed and Convenience in Immunotherapy: The Subcutaneous Shift
Intravenous (IV) cancer infusions create major constraints on time and access . Subcutaneous (SC) immunotherapies open a new era, reducing treatment to minutes, lowering IV-access needs, and improving clinic workflow. With FDA approval on September 19, 2025 , Keytruda Qlex (pembrolizumab + berahyaluronidase alfa-pmph) can now be administered for most approved IV Keytruda indications under the skin .
✅ New Approval: Keytruda Qlex (Subcutaneous Pembrolizumab)
- Indication scope: In adults and pediatric patients aged ≥12, all approved IV pembrolizumab solid-tumor indications.
- Study: MK-3475A-D77 (NCT05722015), involving previously untreated metastatic NSCLC patients negative for EGFR/ALK/ROS1, randomized, multicenter, open-label.
- Patients: 377 (2:1 randomization; SC Qlex + platinum chemotherapy vs IV pembro + platinum chemotherapy).
- Primary aim: Pharmacokinetic comparability (Cycle-1 AUC0–6 weeks and Cycle-3 Ctrough).
Key numerical findings:
- PK equivalence: Lower bounds of geometric mean ratios were above ≥0.8 the threshold.
- Response rate (ORR): 45% (SC) vs. 42% (IV).
- PFS/OS: No significant difference (descriptive analysis).
- Administration time: Depending on dose, approximately 1–2 minutes.
Recommended dose: 395 mg pembro + 4,800 units hyaluronidase (every 3 weeks) or 790 mg pembro + 9,600 units (every 6 weeks), until progression or unacceptable toxicity.
Warnings: Immune-related adverse effects, hypersensitivity/administration reactions, complications of allogeneic stem cell transplantation, embryo-fetal toxicity (see product information).
🌐 The SC Ecosystem: Major Previously Approved Drugs
Phesgo (pertuzumab + trastuzumab + hyaluronidase-zzxf)
Fixed-dose SC combination for HER2-positive breast cancer.
- FDA: June 29, 2020
- Clinical rationale: Two antibodies + enzyme in one injection, without infusions.
Opdivo Qvantig (nivolumab + hyaluronidase-nvhy)
PD-1 inhibitor; SC alternative for most adult solid-tumor indications of IV Opdivo.
- FDA: December 27, 2024
- Administration time: ~5 minutes (CM-67T data)
Tecentriq Hybreza (atezolizumab + hyaluronidase-tqjs)
First SC PD-(L)1; for all adult IV atezolizumab indications.
- FDA: September 12, 2024
- Administration time: ~7 minutes (IMscin001)
Herceptin Hylecta (trastuzumab + hyaluronidase-oysk)
SC trastuzumab formulation for HER2-positive breast cancer.
- FDA: February 28, 2019
- Patient preference: PrefHER reported strong preference for SC.
| Drug (SC) | Class | Administration Time | Dose/Interval (Example) | Key Data |
|---|---|---|---|---|
| Keytruda Qlex | Anti-PD-1 + hyaluronidase | ~1–2 min | 395 mg Q3W or 790 mg Q6W | ORR 45% (SC) vs 42% (IV); PK equivalent |
| Opdivo Qvantig | Anti-PD-1 + hyaluronidase | ~5 min | 600–1200 mg, Q2–4W depending on regimen | CM-67T: PK/efficacy consistent with IV |
| Tecentriq Hybreza | Anti-PD-L1 + hyaluronidase | ~7 min | 1,875 mg/15 mL, Q3W | IMscin001: SC≈IV |
| Herceptin Hylecta | Anti-HER2 + hyaluronidase | Brief administration | Fixed dose, EBC/MBC | HannaH/SafeHER/PrefHER |
🎯 Clinical Impact: For Whom, and When?
- Busy centers: Administration within minutes increases chair turnover and reduces chemotherapy-unit bottlenecks.
- Patients with difficult IV access/port problems: Reduces vascular-access trauma and infusion-related delays.
- Long-term adjuvant/preventive protocols: Supports comfort and adherence.
- Cost–time balance: Regardless of drug cost, gains in health-system efficiency and patient time .
🔭 Looking Ahead: What Should We Expect?
- Wider SC immunotherapy use: In combinations, such as chemo-IO, and adjuvant protocols, an SC-first approach.
- Logistical innovation: Chair time and staffing standards, with discussion of home administration for selected agents/indications.
- Biomarkers and real-world data: Supporting SC/IV equivalence with adherence, quality-of-life, and workforce metrics.
Sources
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.